$ABTI
ALTEROLA BIOTECH INC. Stock $abti

$abti Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000166357723000418 Filed on August 15, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$120.0K	$590.0K	$191.5K
YoY Change	-73.22%	208.05%	1242.19%
% of Gross Profit
Research & Development			$18.47K
YoY Change			-86.45%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$123.2K	$580.7K	$210.0K
YoY Change	-73.83%	176.51%	39.48%
Operating Profit	-$123.2K	-$580.7K	-$210.0K
YoY Change	-73.83%	176.51%	39.48%
Interest Expense	$0.00	$0.00	$0.00
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$123.2K	-$138.2K
YoY Change	323992.11%
Pretax Income	-$120.0K	-$730.0K	-$210.0K
YoY Change	-74.51%	247.62%	39.48%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$123.2K	-$718.8K	-$210.0K
YoY Change	-67.18%	242.3%	39.48%
Net Earnings / Revenue
Basic Earnings Per Share			$0.00
Diluted Earnings Per Share	$0.00	$0.00	-$261.60
COMMON SHARES
Basic Shares Outstanding	807.0M shares	807.0M shares	802.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.00K	$40.00K	$61.54K
YoY Change	-33.91%	-35.0%	15679.49%
Cash & Equivalents	$9.102K	$36.55K	$61.54K
Short-Term Investments
Other Short-Term Assets	$190.0K	$190.0K	$44.03K
YoY Change	44.03%	331.52%	196.7%
Inventory	$975.00	$1.009K	$969.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$197.2K	$231.2K	$119.4K
YoY Change	7.33%	93.71%	683.72%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$300.0K	$12.46M	$12.00M
YoY Change	-97.5%	3.85%
TOTAL ASSETS
Total Short-Term Assets	$197.2K	$231.2K	$119.4K
Total Long-Term Assets	$300.0K	$12.46M	$12.00M
Total Assets	$497.2K	$12.69M	$12.12M
YoY Change	-95.92%	4.73%	79475.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$722.1K	$678.0K	$570.5K
YoY Change	27.35%	18.84%	69.15%
Accrued Expenses	$246.4K	$283.1K	$406.3K
YoY Change	-31.96%	-30.32%	-17.81%
Deferred Revenue
YoY Change
Short-Term Debt	$1.550M	$1.370M	$99.57K
YoY Change	316.97%	1275.92%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.519M	$2.334M	$1.076M
YoY Change	93.66%	116.84%	18.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$151.6K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$151.6K
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.519M	$2.334M	$1.076M
Total Long-Term Liabilities	$0.00	$0.00	$151.6K
Total Liabilities	$2.519M	$2.334M	$1.228M
YoY Change	75.13%	90.07%	215.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.43M	-$10.30M	-$8.181M
YoY Change	15.62%	25.85%
Common Stock	$778.0K	$807.0K	$802.6K
YoY Change	-3.6%	0.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.022M	$10.36M	$10.89M
YoY Change
Total Liabilities & Shareholders Equity	$497.2K	$12.69M	$12.12M
YoY Change	-95.92%	4.73%	79475.57%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$123.2K	-$718.8K	-$210.0K
YoY Change	-67.18%	242.3%	39.48%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$120.0K	-$75.47K	-$165.9K
YoY Change	-39.18%	-54.52%	23009.05%
INVESTING ACTIVITIES
Capital Expenditures		$20.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$40.00K		$0.00
YoY Change
Cash From Investing Activities	$60.00K	-$18.90K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	$68.45K	$1.100K
YoY Change	-96.62%	6122.64%	47.45%
NET CHANGE
Cash From Operating Activities	-120.0K	-$75.47K	-$165.9K
Cash From Investing Activities	60.00K	-$18.90K
Cash From Financing Activities	10.00K	$68.45K	$1.100K
Net Change In Cash	-50.00K	-$25.92K	-$2.274K
YoY Change	-150.73%	1039.75%	1622.73%
FREE CASH FLOW
Cash From Operating Activities	-$120.0K	-$75.47K	-$165.9K
Capital Expenditures		$20.00K
Free Cash Flow		-$95.47K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001442999
CY2023Q2	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q2	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable		usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Revenues Revenues		usd
CY2022Q2	us-gaap	Revenues Revenues		usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q2	us-gaap	Legal Fees LegalFees		usd
CY2022Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q2	ABTI	Stock Issued For Exercise Of Warrants StockIssuedForExerciseOfWarrants		usd
CY2023Q2	ABTI	Increase In Funds In Attorney Trust Account IncreaseInFundsInAttorneyTrustAccount		usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2022Q2	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets		usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q2	ABTI	Shares Issued For Cash Financing SharesIssuedForCashFinancing		usd
CY2023Q2	ABTI	Shares Issued For Stock Subscription SharesIssuedForStockSubscription		usd
CY2022Q2	ABTI	Acquisition Of Treasury Shares AcquisitionOfTreasuryShares		usd
CY2023Q2	us-gaap	Interest Paid InterestPaid		usd
CY2022Q2	us-gaap	Interest Paid InterestPaid		usd
CY2023Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q2	ABTI	Stock Issued For Asset Acquisition StockIssuedForAssetAcquisition		usd
CY2022Q2	ABTI	Stock Issued For Exercise Of Warrants StockIssuedForExerciseOfWarrants		usd
CY2022Q2	ABTI	Stock Issued For Conversion Of Notes Payable StockIssuedForConversionOfNotesPayable		usd
CY2023Q2	dei	Document Type DocumentType	10-Q
CY2023Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q2	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	dei	Entity File Number EntityFileNumber	333-156091
CY2023Q2	dei	Entity Registrant Name EntityRegistrantName	Alterola Biotech, Inc.
CY2023Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1317032
CY2023Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	47 Hamilton Square
CY2023Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Birkenhead Merseyside
CY2023Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	CH41 5AR
CY2023Q2	dei	Entity Address Country EntityAddressCountry	GB
CY2023Q2	dei	City Area Code CityAreaCode	151
CY2023Q2	dei	Local Phone Number LocalPhoneNumber	601 9477
CY2023Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q2	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	807047948	shares
CY2023Q2	us-gaap	Cash Cash	36545	usd
CY2023Q1	us-gaap	Cash Cash	8890	usd
CY2023Q1	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	37593	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	193653	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	189355	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1009	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	986	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	231207	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	237184	usd
CY2023Q2	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12461852	usd
CY2023Q1	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12139779	usd
CY2023Q2	us-gaap	Assets Assets	12693059	usd
CY2023Q1	us-gaap	Assets Assets	12376963	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	677988	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	611805	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	283132	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	254864	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	1372947	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	1260434	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2334067	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2127103	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	154313	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2334067	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2281416	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	807048	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	807048	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19856930	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18929919	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10295080	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9576247	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-9906	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-63173	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	10358992	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10095563	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12693059	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12376963	usd
CY2023Q2	ABTI	Accounting And Audit Fees AccountingAndAuditFees	48938	usd
CY2022Q2	ABTI	Accounting And Audit Fees AccountingAndAuditFees	34917	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	5290	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	2396	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18472	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	2611	usd
CY2023Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	171000	usd
CY2022Q2	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	496788	usd
CY2023Q2	ABTI	Consulting Fees ConsultingFees	317741	usd
CY2022Q2	ABTI	Consulting Fees ConsultingFees	127419	usd
CY2023Q2	us-gaap	Salaries And Wages SalariesAndWages	35939	usd
CY2022Q2	us-gaap	Salaries And Wages SalariesAndWages	97428	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1762	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32658	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	580670	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	812689	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-580670	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-812689	usd
CY2023Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-138163	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-138163	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-718833	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-812689	usd
CY2023Q2	ABTI	Income Loss From Continuing Operations Per Basic IncomeLossFromContinuingOperationsPerBasic	-0.00
CY2022Q2	ABTI	Income Loss From Continuing Operations Per Basic IncomeLossFromContinuingOperationsPerBasic	-0.00
CY2023Q2	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	807047948	shares
CY2022Q2	ABTI	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	802633333	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11062996	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175074	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	280	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	321000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	481500	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-812689	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11278161	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10095563	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	157339	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	295000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	305672	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	171000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53267	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-718833	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	10358992	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-718833	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-812689	usd
CY2023Q2	ABTI	Stock Issued For Outside Services StockIssuedForOutsideServices	371760	usd
CY2022Q2	ABTI	Stock Issued For Outside Services StockIssuedForOutsideServices	321000	usd
CY2023Q2	ABTI	Stock Issued To Directors StockIssuedToDirectors	180000	usd
CY2022Q2	ABTI	Stock Issued To Directors StockIssuedToDirectors	481500	usd
CY2023Q2	ABTI	Stock Issued For Exercise Of Warrants StockIssuedForExerciseOfWarrants	13500	usd
CY2022Q2	ABTI	Increase In Funds In Attorney Trust Account IncreaseInFundsInAttorneyTrustAccount	12409	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	81	usd
CY2023Q2	ABTI	Increase Decrease In Vat Taxes Receivable IncreaseDecreaseInVATTaxesReceivable	65198	usd
CY2022Q2	ABTI	Increase Decrease In Vat Taxes Receivable IncreaseDecreaseInVATTaxesReceivable	37867	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-250090	usd
CY2023Q2	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-4298	usd
CY2022Q2	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-44030	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	38938	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	27999	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	28268	usd
CY2022Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9832	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-75467	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-216121	usd
CY2023Q2	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	-18900	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18900	usd
CY2023Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	-112513	usd
CY2022Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	-1100	usd
CY2022Q2	ABTI	Shares Issued For Cash Financing SharesIssuedForCashFinancing	50000	usd
CY2022Q2	ABTI	Shares Issued For Stock Subscription SharesIssuedForStockSubscription	280	usd
CY2023Q2	ABTI	Acquisition Of Treasury Shares AcquisitionOfTreasuryShares	-44064	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68449	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51380	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25918	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-164741	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Excluding Investment Price Change After Tax ForeignCurrencyTransactionGainLossExcludingInvestmentPriceChangeAfterTax	53573	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Excluding Investment Price Change After Tax ForeignCurrencyTransactionGainLossExcludingInvestmentPriceChangeAfterTax	162469	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8890	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63814	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36545	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61542	usd
CY2023Q2	ABTI	Stock Issued For Services StockIssuedForServices	321760	usd
CY2022Q2	ABTI	Stock Issued For Services StockIssuedForServices	321000	usd
CY2023Q2	ABTI	Stock Issued To Directors StockIssuedToDirectors	180000	usd
CY2022Q2	ABTI	Stock Issued To Directors StockIssuedToDirectors	481500	usd
CY2023Q2	ABTI	Stock Issued For Asset Acquisition StockIssuedForAssetAcquisition	300000	usd
CY2023Q2	ABTI	Stock Issued For Exercise Of Warrants StockIssuedForExerciseOfWarrants	13500	usd
CY2023Q2	ABTI	Stock Issued For Conversion Of Notes Payable StockIssuedForConversionOfNotesPayable	157815	usd
CY2023Q2	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zUtFfsZfB1x9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – NATURE OF BUSINESS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After formation, the Company was in the business of mineral exploration. On May 3, 2010, the Company sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20100402__20100503__us-gaap--StatementEquityComponentsAxis__custom--IssuanceOneMember_pdd">55,000,000</span> shares of the Company’s common stock.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the acquisition of the IP the Company changed its business direction to pursue the development of chewing gums for the delivery of Nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 19, 2021, the Company entered into an Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210101__20210129__us-gaap--StatementEquityComponentsAxis__custom--IssuanceTwoMember_pdd">600,000,000</span> shares of the Company pro rata to the ABTI Pharma shareholders. The shares were issued on January 29, 2021 in anticipation of the closing and the parties to the transaction agreed in a March 24, 2021 amendment to close upon the ABTI Pharma Limited Shares being transferred to the Company, which was to occur upon the filing by the Company of its outstanding December 31, 2020 quarterly report on Form 10-Q, which was filed on May 28, 2021 with the Securities and Exchange Commission. The transaction closed on May 28, 2021.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction is being accounted for as a reverse acquisition and recapitalization. ABTI Pharma is the acquirer for accounting purposes and the Company is the issuer. The historical financial statements presented are the financial statements of ABTI. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were <span id="xdx_90A_eus-gaap--Liabilities_c20210528_pp0p0">$389,721</span>.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The business plan of the company will no longer be focused on a chewing gum delivery system but it will re-focus its activities to the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products .In addition, the company plans to develop such bulk ingredients for supply into the cosmetic sector.</span></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 05, 2023 we acquired intellectual property from Alinova Biosciences Ltd. We acquired Alinova’s joint interest in the patent family PTX P0001. We paid total upfront costs of £<span id="xdx_90B_eus-gaap--AcquisitionCosts_c20230705__20230705__us-gaap--AssetAcquisitionAxis__custom--PatentPTXMember_zHaEp6eBC8B9">35,000</span> Sterling in cash and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20230705__20230705__us-gaap--AssetAcquisitionAxis__custom--PatentPTXMember_zLQox3LCpVd6">5,000,000</span> shares of ABTI stock.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2	us-gaap	Liabilities Liabilities	389721	usd
CY2023Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zko7RAdBp3Jf" style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	7500000	shares
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	12000000	usd
CY2023Q2	us-gaap	Development Costs Cumulative DevelopmentCostsCumulative	0	usd
CY2023Q1	us-gaap	Development Costs Cumulative DevelopmentCostsCumulative	0	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	520000	shares
CY2021Q4	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	130000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	44064000	shares
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	283132	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	254864	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	807047948	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	807047948	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	807047948	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	807047948	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Loans Held For Sale Term LoansHeldForSaleTerm	P90D
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	75000	usd
CY2022Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	2250000	shares
	us-gaap	Repayments Of Longterm Loans From Vendors RepaymentsOfLongtermLoansFromVendors	75000	usd
CY2023Q2	ABTI	Shareholder Advances ShareholderAdvances	1372947	usd
CY2023Q2	us-gaap	Capital Capital	2102860	usd
	us-gaap	Profit Loss ProfitLoss	-10295080	usd

Files In Submission

Name	View Source	Status
0001663577-23-000418-index-headers.html	Edgar Link	pending
0001663577-23-000418-index.html	Edgar Link	pending
0001663577-23-000418.txt	Edgar Link	pending
0001663577-23-000418-xbrl.zip	Edgar Link	pending
abti-20230630.xsd	Edgar Link	pending
abti10q_063023.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
abti-20230630_def.xml	Edgar Link	unprocessable
abti-20230630_cal.xml	Edgar Link	unprocessable
abti-20230630_pre.xml	Edgar Link	unprocessable
abti-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abti10q_063023_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABTI
ALTEROLA BIOTECH INC. Stock $abti

2023 Q3 Form 10-Q Financial Statement

#000166357723000418 Filed on August 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABTI ALTEROLA BIOTECH INC. Stock $abti

2023 Q3 Form 10-Q Financial Statement

#000166357723000418 Filed on August 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABTI
ALTEROLA BIOTECH INC. Stock $abti